依折麦布与海博麦布的药品遴选实践  

Practice of Drug Selection of Eezetimibe and Hybutimibe

作　　者：高媛 王晓倩 张之晗 李从欣 GAO Yuan;WANG Xiaoqian;ZHANG Zhihan;LI Congxin(Dept.of Pharmacy,the Third Hospital of Hebei Medical University,Shijiazhuang 050051,China;Dept.of Clinical Nutrition,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China)

机构地区：[1]河北医科大学第三医院药剂科,石家庄050051 [2]河北医科大学第四医院临床营养科,石家庄050011

出　　处：《中国医院用药评价与分析》2024年第1期75-80,共6页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家自然科学基金资助项目(No.82003878);河北省自然科学基金资助项目(No.H2021206026);河北省高等学校科学研究青年拔尖人才项目(No.BJ2021053)。

摘　　要：目的:对依折麦布和海博麦布进行评价,为医疗机构遴选胆固醇吸收抑制剂提供依据。方法:依据《中国医疗机构药品评价遴选快速指南》,采用量化评分的评估体系,参考药品说明书、诊疗规范、临床指南、专家共识等,对万方数据库、中国知网、维普数据库、Embase和PubMed等数据库进行检索。从药学特性、有效性、安全性、经济性、国家医保、基本药物、贮藏条件、药品有效期、全球使用和生产企业状况等10个方面对依折麦布和海博麦布进行评分,并根据评分对推荐级别进行划分。结果:依折麦布、海博麦布的评分分别为72.4、67.6分。两药均为胆固醇吸收抑制剂,在治疗高胆固醇血症方面有独特的优势,依折麦布作为经典药物受到诸多指南的一级推荐;海博麦布作为新药,在长期用药的安全性及经济性方面略优。结论:依折麦布和海博麦布在不同属性中各有优势,本次药品遴选可为医疗机构提供循证依据。OBJECTIVE:To evaluate eezetimibe and hybutimibe,so as to provide evidence for medical institutions to select cholesterol absorption inhibitors.METHODS:According to the Quick Guideline for Drug Evaluation and Selection in Chinese Medical Institutions,quantitative scoring evaluation system was adopted,Wanfang Data,CNKI,VIP,Embase and PubMed databases were searched with reference to drug instructions,diagnosis and treatment specifications,clinical guidelines and expert consensus.Ezetimibe and haberimibe were scored in 10 aspects,including pharmacological properties,efficacy,safety,economy,national health insurance,essential medicines,storage conditions,expiration date of the drug,global use,and status of the manufacture,and the level of recommendation was classified according to the scores.RESULTS:Final scores of eezetimibe and hybutimibe were 72.4 and 67.6 points,respectively.Both drugs were cholesterol absorption inhibitors and had unique advantages in the treatment of hypercholesterolemia.Ezetimibe,as a classical drug,was recommended by many guidelines as a first-tier drug.Habermeibe,as a new drug,was slightly better in terms of safety and economy of long-term use.CONCLUSIONS:Ezetimibe and haberimibe have their own advantages in different attributes,and this drug selection may provide an evidence-based basis for healthcare organizations.

关 键 词：药品遴选 胆固醇吸收抑制剂 依折麦布 海博麦布 高胆固醇血症 

分 类 号：R972.6[医药卫生—药品]